Concord Drugs Ltd vs Gennex Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Concord Drugs Ltd is ₹ 84.27 as of 04 May 11:18 . The P/E Ratio of Concord Drugs Ltd changed from 15.9 on March 2022 to 0 on March 2021 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Gennex Laboratories Ltd changed from 24.3 on March 2022 to 12.2 on March 2021 . This represents a CAGR of -12.87% over 5 years The Market Cap of Concord Drugs Ltd changed from ₹ 25.36 crore on March 2022 to ₹ 0 crore on March 2021 . This represents a CAGR of -100.00% over 5 yearsThe Market Cap of Gennex Laboratories Ltd changed from ₹ 95.26 crore on March 2022 to ₹ 49.46 crore on March 2021 . This represents a CAGR of -12.29% over 5 years The revenue of Concord Drugs Ltd for the Dec '25 is ₹ 16.99 crore as compare to the Sep '25 revenue of ₹ 10.28 crore. This represent the growth of 65.27% The revenue of Gennex Laboratories Ltd for the Dec '25 is ₹ 42.96 crore as compare to the Sep '25 revenue of ₹ 39.3 crore. This represent the growth of 9.31% The ebitda of Concord Drugs Ltd for the Dec '25 is ₹ 0.94 crore as compare to the Sep '25 ebitda of ₹ 1.1 crore. This represent the decline of -14.55% The ebitda of Gennex Laboratories Ltd for the Dec '25 is ₹ 8.27 crore as compare to the Sep '25 ebitda of ₹ 7.56 crore. This represent the growth of 9.39% The net profit of Concord Drugs Ltd changed from ₹ 0.03 crore to ₹ 0.22 crore over 7 quarters. This represents a CAGR of 212.22% The net profit of Gennex Laboratories Ltd changed from ₹ 4.66 crore to ₹ 5.99 crore over 7 quarters. This represents a CAGR of 15.43% The Dividend Payout of Concord Drugs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Gennex Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Concord Drugs Ltd

Concord Drugs Limited, established in 1995, is amongst the respected pharmaceutical companies in India for manufacturing of Finished Pharmaceutical Formulations like Injectables (Small Volume parenterals, Dry Syrup powder) ,Tissue Bio-Adhesive, tablets, capsules and ophthalmic preparations and Ready-to-fill Pellets. The principal activity of the Company is to manufacture licensed drugs based on the formulations approved.
The Company has two manufacturing facilities license issued by The Government of Andhra Pradesh, Drugs Control Administration, and Hyderabad.
State of the art technology having dedicated manufacturing facilities for Liquid Injections, Dry powder Injections and Ready-to-fill Pellets ensures the highest level of process integrity and product quality. The Company started with Finished Pharmaceutical Formulations and then diversified into Ready-to-fill Pellets, to provide customers with end-to-end solution to their various pharmaceutical product needs to commercial contract drug manufacturing.

About Gennex Laboratories Ltd

Gennex Laboratories Limited, formerly known as Prudential Pharmaceuticals Limited was incorporated on June 25, 1985.
The Company got converted into a Public Limited Company and the name was changed from Prudential Pharmaceuticals Limited to Gennex Laboratories Limited in 2007. The Company is in the business of Manufacturing of Bulk Drugs, Intermediates and Biotech Products.
The Company has over the years added more capacity and infrastructure by way of an additional production block and equipment to the plant to handle more products and tonnages.
The Company is having a professionally managed team at every stage of its operations. Apart from these, Gennex is among the leading Vertically Integrated' pharmaceutical companies in India and has a robust product portfolio spread over major product segments encompassing Expectorants, Muscle Relaxants, Analgesic and Anti Fungal.

FAQs for the comparison of Concord Drugs Ltd and Gennex Laboratories Ltd

Which company has a larger market capitalization, Concord Drugs Ltd or Gennex Laboratories Ltd?

Market cap of Concord Drugs Ltd is 112 Cr while Market cap of Gennex Laboratories Ltd is 242 Cr

What are the key factors driving the stock performance of Concord Drugs Ltd and Gennex Laboratories Ltd?

The stock performance of Concord Drugs Ltd and Gennex Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Concord Drugs Ltd and Gennex Laboratories Ltd?

As of May 4, 2026, the Concord Drugs Ltd stock price is INR ₹85.13. On the other hand, Gennex Laboratories Ltd stock price is INR ₹9.99.

How do dividend payouts of Concord Drugs Ltd and Gennex Laboratories Ltd compare?

To compare the dividend payouts of Concord Drugs Ltd and Gennex Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.